The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells

Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes

(2015) Yogen Saunthararajah et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia

(2014) Yi-Bin Chen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Targeting FLT3 to treat leukemia

(2014) Heiko Konig et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

FLT3 inhibitor-induced neutrophilic dermatosis

(2013) A. T. Fathi et al.   BLOOD

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

(2013) F. Ravandi et al.   BLOOD

Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase

(2013) Xiaochuan Yang et al.   BRITISH JOURNAL OF HAEMATOLOGY

FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance

(2013) Michael R. Grunwald et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial

(2013) Hubert Serve et al.   JOURNAL OF CLINICAL ONCOLOGY

Prolonged Treatment with DNMT Inhibitors Induces Distinct Effects in Promoters and Gene-Bodies

(2013) Yan-Fung Wong et al.   PLoS One

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

(2012) J. Aimiuwu et al.   BLOOD

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

(2012) A. Sexauer et al.   BLOOD

Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation

(2012) C. H. Man et al.   BLOOD

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies

(2012) Yogen Saunthararajah et al.   SEMINARS IN ONCOLOGY

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

(2011) M. Levis et al.   BLOOD

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

(2011) M. Lubbert et al.   HAEMATOLOGICA

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

(2011) D A Pollyea et al.   LEUKEMIA

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

(2010) Paul W. Hollenbach et al.   PLoS One

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

(2009) K. W. Pratz et al.   BLOOD

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

(2009) Amanda F. Cashen et al.   JOURNAL OF CLINICAL ONCOLOGY

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

(2009) C Flotho et al.   LEUKEMIA

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia

(2008) Weiguo Zhang et al.   JNCI-Journal of the National Cancer Institute